DPP3 triggers myocardial depressionResults presented at European Society of Cardiology Congress 2019 demonstrate a new disease mechanism predicting acute organ dysfunction in heart failure patients. more ➔
Pro-apoptotic protein blocks autoimmunity A US-EU research team has found that a class of compounds that promote tumour cell death can also limit autoimmunity. more ➔
Immatics and Celgene enter $1.5bn dealCelgene will pay $75m upfront to get an option on three cancer programmes developed by Immatics Biotechnologies. more ➔
Microbial feed company Unibio raises US$15... Danish microbiology specialist Unibio International plc had completed a US$15m financing round led by West Hill Capital. more ➔
ADC Therapeutics and Freenome enter biomar...US company Freenome will use its multiomics platform to develop response biomarkers to ADC Therapeutics Phase II antibody drug conjugate (ADC) ADCT-402. more ➔
GSK reaches endpoint in pivotal blood canc...GlaxoSmithKline plc announced belantamab mafodotin (GSK2857916) met the primary endpoint of overall response rate (ORR) in a pivotal Phase II trial in treatment-refractive multiple myeloma. more ➔
Swiss researchers report on metastasis swi... Researchers from Paul Scherrer Institute in Villingen, Switzerland, and Hoffmann La-Roche AG report in Cell they have solved the structure of a target relevant in metastasis. more ➔
Preclinical antibody stops rheumatoid arth... An antibody therapy that targets red blood cells (RBCs) unexpectedly showed anti-inflammatory effects and rapidly reversed rheumatoid arthritis and prevented lung injury in mouse models. more ➔
Nabriva receives FDA approval for novel an...Nabriva Therapeutics plc has got the go from the FDA to market its pleuromutilin antibiotic Xenleta (lefamulin), a protein synthesis blocker with new mode-of-action to treat community-acquired bacterial … more ➔
Araris Biotech AG kicks-off with CHF2.5m s... Zurich-based ADC maker Araris Biotech AG announced the closing of an oversubscribed seed financing round of CHF2.5m with Redalpine, Schroder Adveq and VI Partners contibuting. more ➔
